Efficacy and tolerability of imiquimod 5% cream to treat periocular basal cell carcinomas

Journal of Ocular Pharmacology and Therapeutics

Volumn 26, Issue 4, 2010, Pages 373-379

  Garcia Martin, Elena ^a,b   Idoipe, Miriam ^a   Gil, Laura Maria ^a   Pueyo, Victoria ^a,b   Alfaro, Jorge ^b   Pablo, Luis E ^a,b   Zubiri, Maria Luisa ^b   Fernandez, Javier ^a  

^a Miguel Servet Universitary Hospital   (Spain)

^b HOSPITAL UNIVERSITARIO MIGUEL SERVET   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

IMIQUIMOD;

ADULT; AGED; ARTICLE; BASAL CELL CARCINOMA; CLINICAL ARTICLE; DRUG EFFECT; DRUG EFFICACY; DRUG TOLERABILITY; EYE CANCER; FEMALE; FOLLOW UP; HISTOPATHOLOGY; HUMAN; MALE; OUTCOME ASSESSMENT; PERIOCULAR NODULAR BASAL CELL CARCINOMA; REMISSION; TREATMENT DURATION;

ACRYLIC RESINS; ADMINISTRATION, CUTANEOUS; AGED; AGED, 80 AND OVER; AMINOQUINOLINES; ANTINEOPLASTIC AGENTS; CARCINOMA, BASAL CELL; CRYOTHERAPY; EYELID NEOPLASMS; EYELIDS; FEMALE; HUMANS; MALE; MIDDLE AGED; PHOTOCHEMOTHERAPY; SKIN NEOPLASMS; TREATMENT OUTCOME;

EID: 77955576614     PISSN: 10807683     EISSN: None     Source Type: Journal    
DOI: 10.1089/jop.2010.0030     Document Type: Article

References (36)

1. Allali, J., D'Hermies, F., and Renard, G. Basal cell carcinomas of the eyelids. Ophthalmologica 219:57-71, 2005.
2. Christenson, L.J., Borrowman, T.A., Vachon, C.M., Tollefson, M.M., Otley, C.C., Weaver, A.L., and Roenigk, R.K. Increasing incidence of nonmelanoma skin cancers in those younger than 40 years. JAMA 294:681-690, 2005.
3. Marks, R., Staples, M., and Giles, G.G. Trends in non-melanoma skin cancer treated in Australia: the second national survey. Int. J. Cancer 53:585-590, 1993.
4. Bogelund, F.S., Philipsen, P.A., and Gniadecki, R. Factors affecting the recurrence rate of basal cell carcinoma. Acta Derm. Venereol. 87:330-334, 2007.
5. Levin, F., Khalil, M., McCormick, S.A., Della Rocca, D., Maher, E., and La Rocca, R.C. Excision of periocular basal cell carcinoma with stereoscopic microdissection of surgical margins for frozen-section control: report of 200 cases. Arch. Ophthalmol. 127:1011-1015, 2009.
6. Whitaker, D.C., Goldstein, G.D., Birkby, C.S., and Nerad, J.A. Postoperative techniques for corneal protection in Mohs micrographic surgery. J. Dermatol. Surg. Oncol. 14:951-955, 1994.
7. Blasi, M.A., Giammaria, D., and Balestrazzi, E. Immunotherapy with imiquimod 5% cream for eyelid nodular basal cell carcinoma. Am. J. Ophthalmol. 140:1136-1139, 2005.
8. Huber, A., Huber, J.D., Skinner Jr., R.B., Kuwahara, R.T., Haque, R., and Amonette, R.A. Topical imiquimod treatment for nodular basal cell carcinomas: an openlabel series. Dermatol. Surg. 30:429-430, 2004.
9. Beutner, K.R., Geisse, J.K., Helman, D., Fox, T.L., Ginkel, A., and Owens, M.L. Therapeutic response of basal cell carcinoma to the immune response modifier imiquimod 5% cream. J. Am. Acad. Dermatol. 41:1002-1007, 1999.
10. Shumack, S., Robinson, J., Kossard, S., Golitz, L., Greenway, H., Schroeter, A., Andres, K., Amies, M., and Owens, M. Efficacy of topical 5% imiquimod cream for the treatment of nodular basal cell carcinoma. Arch. Dermatol. 138:1165-1171, 2002.
11. Hemmi, H., Kaisho, T., Takeuchi, O., Sato, S., Sanjo, H., Hoshino, K., Horiuchi, T., Tomizawa, H., Takeda, K., and Akira, S. Small antiviral compounds activate immune cells via the TLR7 MyD88-dependent signaling pathway. Nat. Immunol. 3:196-200, 2002.
12. Geisse, J., Caro, L., Lindholm, J., Golitz, L., Stampone, P., and Owens, M. Imiquimod 5% cream for the treatment of superficial basal cell carcinoma: results from two phase III, randomized, vehicle-controlled studies. J. Am. Acad. Derma-tol. 50:722-735, 2004.
13. Peris, K., Campione, E., Micantonio, T., Marulli, G.C., Fargnoli, M.C., and Chimenti, S. Imiquimod treatment of superficial and nodular basal cell carcinoma: 12-week open-label trial. Dermatol. Surg. 31:318-323, 2005.
14. Schiessl, C., Wolber, C., Tauber, M., Offner, F., and Strohal, R. Treatment of all basal cell carcinoma variants including large and high-risk lesions with 5% imiquimod cream: his-tological and clinical changes, outcome, and follow-up. J. Drugs Dermatol. 6:507-513, 2007.
15. Margo, C., and Waltz, K. Basal cell carcinoma of the eyelid and periocular skin. Surv. Ophthalmol. 38:169-192, 1993.
16. Silverman, M.K., Kopf, A.W., Grin, C.M., Bart, R.S., and Levenstein, M.J. Recurrence rates of treated basal cell carcinomas. Part 2: curettage- electrodesiccation. J. Dermatol. Surg. Oncol. 17:720-726, 1991.
17. Malhotra, R., Huilgol, S.C., Huynh, N.T., and Selva, D. The Australian Mohs database, part II. Periocular basal cell carcinoma outcome at 5-year follow-up. Ophthalmology 111:631636, 2004.
18. NCCN Clinical Practice Guidelines in Oncology. Basal Cell and Squamous Cell Skin Cancers. 2007. Available at www.nccn.org/professionals/physician-gls/ PDF/nmsc.pdf (accessed October 2007).
19. Bath-Hextall, F.J., Perkins, W., Bong, J., and Williams, H.C. Interventions for basal cell carcinoma of the skin. Cochrane Database Syst. Rev. 1: CD003412.
20. Ceilley, R.I., and Del Rosso, J.Q. Current modalities and new advances in the treatment of basal cell carcinoma. Int. J. Dermatol. 45:489-498, 2006.
21. Kopf, A.W., Bart, R.S., Schrager, D., Lazar, M., and Popkins, G. Curettage-electrodesiccation treatment of basal cell carcinomas. Arch. Dermatol. 113:439-443, 1977.
22. Salasche, S. Status of curettage and electrodesiccation in the treatment of primary basal cell carcinoma. J. Am. Acad. Dermatol. 10:285-287, 1984.
23. Suhge d'Aubermont, P.C., and Bennett, R.G. Failure of curettage and electrodesiccation for removal of basal cell carcinoma. Arch. Dermatol. 120:1456-1460, 1984.
24. Berman, B. Scientific rationale: combining imiquimod and surgical treatments for basal cell carcinomas. J. Drugs Dermatol. 7(1 Suppl 1):s3-s6, 2008.
25. Vidal, D., Matias-Guiu, X., and Alomar, A. Fifty-five basal cell carcinomas treated with topical imiquimod: outcome at 5-year follow-up. Arch. Dermatol. 143:266-268, 2007.
26. Tillman, D.K., and Carroll, M.T. A 36-month clinical experience of the effectiveness of curettage and imiquimod 5% cream in the treatment of basal cell carcinoma. J. Drugs Dermatol. 7(1 Suppl 1):s7-s14, 2008.
27. Wu, J.K., Oh, C., Strutton, G., and Siller, G. An open-label, pilot study examining the efficacy of curettage followed by imiquimod 5% cream for the treatment of primary nodular basal cell carcinoma. Australas. J. Dermatol. 47:46-48, 2006.
28. Szeimies, R.M. Methyl aminolevulinate-photodynamic therapy for basal cell carcinoma. Dermatol. Clin. 25:89-94, 2007.
29. Rhodes, L.E., De Rie, M., Enstrom, Y., Groves, R., Morken, T., Goulden, V., Wong, G.A., Grob, J.J., Varma, S., and Wolf, P. Photodynamic therapy using topical methyl aminolevu-linate vs surgery for nodular basal cell carcinoma: results of a multicenter randomized prospective trial. Arch. Dermatol. 140:17-23, 2004.
30. Rhodes, L.E., de Rie, M.A., Leifsdottir, R., Yu, R.C., Bach-mann, I., Goulden, V., Wong, G.A., Richard, M.A., Anstey, A., and Wolf, P. Five year follow up of a randomized, prospective trial of topical methyl aminolevulinate photody-namic therapy vs surgery for nodular basal cell carcinoma. Arch. Dermatol. 143:1131-1136, 2007.
31. Rigel, D.S., Torres, A.M., and Ely, H. Imiquimod 5% cream following curettage without electrodesiccation for basal cell carcinoma: preliminary report. J. Drugs Dermatol. 7(1 Suppl 1):s15-s16, 2008.
32. Spencer, J.M. Pilot study of imiquimod 5% cream as ad-junctive therapy of curettage and electrodesiccation for nodular basal cell carcinoma. Dermatol. Surg. 32:63-69, 2006.
33. Peng, Q., Warloe, T., Berg, K., Moan, J., Kongshaug, M., Giercksky, K.E., and Nesland, J.M. 5-Aminolevulinic acid-based photodynamic therapy. Clinical research and future challenges. Cancer 79:2282-2308, 1997.
34. Caekelbergh, K., Annemans, L., Lambert, J., and Roelandts, R. Economic evaluation of methyl aminolaevulinate-based photodynamic therapy in the management of actinic kera-tosis and basal cell carcinoma. Br. J. Dermatol. 155:784-790, 2006.
35. Karve, S.J., Feldman, S.R., Yentzer, B.A., Pearce, D.J., and Balkrishnan, R. Imiquimod: a review of basal cell carcinoma treatments. J. Drugs Dermatol. 7:1044-1051, 2008.
36. Rowe, D.E., Carroll, R.J., and Doy Jr., C.L. Long term recurrence rates in previously untreated (primary) basal cell carcinoma: implications for patient follow up. J. Derm. Surg. Oncol. 15:315-328, 1989.